Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...
InsideNoVa3h
Novo Nordisk To Pay $2 Billion for New Weight Loss Drug
Novo Nordisk will pay $200 million up front, with up to $1.8 billion in additional payments down the line, The Wall Street ...
STAT3h
Novo Nordisk follows Eli Lilly with its own ‘triple-G’ drug
Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.
Step Aside, Novo Nordisk. This Is Europe’s No. 1 Company Now.
The two stocks have been trending in different directions for months. Here's what that says about the broader market.
pharmaphorum19h
When licensing deals go bad - Novo sues KBP Bio for $830m
Novo Nordisk has accused Singapore-based biotech KBP Biosciences of concealing clinical data ahead of a $1.3 billion licensing agreement between the two companies in 2023 focused on blood pressure ...
yr.no19h
Novo Mesto
It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...